secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2025-12-01T23:59:59+00:00
Accession:  0001867096-25-000161
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma receives USPTO Notice of Allowance for XP-8121 patent application
--------------------------------------------------------------------------------

- Patent allowance covers XP-8121 formulation for hypothyroidism, a novel product candidate.
- Notice of Allowance indicates patentability; U.S. patent expected after administrative steps.
- CEO John Shannon highlights milestone for meeting unmet medical need in hypothyroidism.
- Xeris continues pursuing additional U.S. and international IP protection for LT4 technology.
- XP-8121 leverages XeriSol platform for subcutaneous injection of difficult-to-formulate drugs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000161/0001867096-25-000161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709625000161/xers-20251201.htm
  HTML page:      https://secwatch.observer/filing/0001867096-25-000161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer